🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gulden Menderes

Smilow Cancer Hospital

ORCID: 0000-0002-3140-3860
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability”.

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer(2021)10.1002/cncr.34025
N/A
2.4DataRank · unranked
80 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Annals of Oncology(2021)10.1016/j.annonc.2021.04.013
N/A
1.9DataRank · unranked
50 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00118
N/A
0DataRank · unranked
64 citations

Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra +17 more

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.06.484
N/A
0DataRank · unranked
4 citations

Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra +15 more

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.05.005
N/A
0DataRank · unranked
25 citations

Paola Manara, Diego Manavella, Stefania Bellone, Tobias M.P. Hartwich, Justin Harold +17 more